Core Insights - Zomedica Corp. is enhancing its commitment to pet wellness education through a collaboration with Prime Video, featuring its Assisi and Calmer Canine products in the movie Merv [1] Company Overview - Zomedica is an animal health company that provides innovative diagnostic and therapeutic devices for equine and companion animals [1] Industry Impact - The inclusion of Zomedica's technologies in a popular romantic comedy aims to raise awareness and educate the public about pet wellness [1]

Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment ANN ARBOR, MI / ACCESS Newswire / December 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA platform with the launch of its equine progesterone assay, designed as a po ...

Core Viewpoint - Zomedica Corp. is hosting a special session of its "Fourth Friday at Four" investor webinar series to provide strategic context for its product platforms, with the session scheduled for November 21, 2025 [1] Group 1 - The webinar will take place on the third Friday of November to accommodate the holiday calendar [1] - The session aims to highlight Zomedica's innovative diagnostic and therapeutic devices for equine and companion animals [1]

Core Insights - Zomedica Corp. has achieved ISO 13485:2016 certification for its manufacturing and distribution operations, enhancing its commitment to quality and compliance [1] Company Summary - The certification applies to Zomedica's facilities in Plymouth, Minnesota, and Roswell, Georgia, reinforcing the company's operational standards [1] - This milestone supports Zomedica's long-term growth strategy and readiness for global markets [1]

Core Insights - Zomedica reported its highest quarterly revenue ever for the third quarter ended September 30, 2025, marking a record year-over-year revenue for the 19th consecutive quarter [1] Financial Performance - The company achieved significant financial growth, with consolidated financial results indicating a strong performance in the animal health sector [1] - The report highlights the effectiveness of Zomedica's point-of-care diagnostic and therapeutic products for equine and companion animals, contributing to the revenue increase [1]

Core Insights - Zomedica Corp. has launched the Assisi Loop Lounge, a next-generation targeted pulsed electromagnetic field (tPEMF) therapy bed designed for pets, emphasizing both therapeutic effectiveness and comfort [1] - The Assisi Loop Lounge offers unlimited uses and a lifetime warranty, enhancing its value proposition for pet owners and veterinary professionals [1] - This product is distinguished as the only small animal tPEMF device supported by peer-reviewed scientific research, establishing its credibility among veterinarians and pet owners globally [1] Company Overview - Zomedica is an animal health company focused on innovative point-of-care diagnostic and therapeutic products for equine and companion animals [1] - The introduction of the Assisi Loop Lounge expands Zomedica's evidence-based therapeutic portfolio, reinforcing its leadership in the tPEMF innovation space [1] Product Features - The Assisi Loop Lounge provides full-body treatment, combining superior comfort with advanced therapeutic technology [1] - The product is designed to deliver lasting therapeutic value, making it a trusted choice in the veterinary market [1]

Core Insights - Zomedica has entered into an expanded distribution agreement with Grovet b.v., enhancing its presence in the European market and broadening its product portfolio [1] - This agreement positions Zomedica to capture growth opportunities in the multi-billion-dollar global veterinary diagnostics and therapeutic device markets [1] Company Developments - The expanded agreement with Grovet b.v. is aimed at strengthening Zomedica's distribution capabilities in Europe [1] - Zomedica specializes in innovative point-of-care diagnostic and therapeutic device products for equine and companion animals [1] Market Implications - The partnership is expected to facilitate Zomedica's entry into a growing market, which is characterized by increasing demand for veterinary diagnostics and therapeutic devices [1] - The global veterinary diagnostics and therapeutic device markets are projected to be worth several billion dollars, indicating significant growth potential for Zomedica [1]

Core Insights - Zomedica Corp. is set to host a webinar on October 24, 2025, focusing on its VETGuardian Zero Touch monitoring platform, which aims to enhance patient care and improve workflow efficiency [1] Company Overview - Zomedica is a veterinary health company that provides innovative point-of-care diagnostic and therapeutic device products for both equine and companion animals [1] Product Highlight - The VETGuardian Monitor is designed to enhance patient care, improve workflow efficiency, and expand global market opportunities [1]

Core Viewpoint - Zomedica Corp. has expanded its TRUFORMA diagnostic platform to include feline testing capabilities for its cobalamin and folate assay, marking a significant advancement in veterinary diagnostics [1] Group 1: Product Development - The TRUFORMA diagnostic platform now offers a multiplexed assay that combines cobalamin and folate testing, which was previously available only for canine patients [1] - This assay is the first of its kind to provide both cobalamin and folate testing in an in-clinic setting, enhancing the diagnostic capabilities for veterinarians [1] Group 2: Market Position - Zomedica is positioned as an innovative veterinary health company focused on point-of-care diagnostic and therapeutic device products for both equine and companion animals [1]

Core Insights - Zomedica Corp. has strengthened its intellectual property portfolio with the issuance of four additional U.S. patents for its TRUVIEW and TRUFORMA diagnostic platforms [1] - The veterinary diagnostics market is currently valued between $8 billion and $11 billion and is projected to grow to $17 billion to $22 billion by 2030-2032, with a compound annual growth rate (CAGR) of 9-11% [1] Company Summary - Zomedica now holds a total of 228 patents and 153 trademarks, providing robust protection for its product platforms [1] - The company focuses on innovative point-of-care diagnostic and therapeutic device products for equine and companion animals [1]